|Bid||19.45 x 800|
|Ask||19.45 x 1200|
|Day's Range||19.41 - 20.60|
|52 Week Range||14.13 - 56.85|
|Beta (3Y Monthly)||0.59|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 31, 2017 - Nov 6, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||33.50|
NEW YORK, July 19, 2019 -- Levi & Korsinsky announces it has commenced an investigation of AxoGen, Inc. (NASDAQCM: AXGN) concerning possible breaches of fiduciary duty. To.
We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is...
Is AxoGen, Inc. (NASDAQ:AXGN) a good stock to buy right now? We at Insider Monkey like to examine what billionaires and hedge funds think of a company before doing days of research on it. Given their 2 and 20 payment structure, hedge funds have more incentives and resources than the average investor. The funds have […]
Axogen, Inc. (AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that members of its management team will participate in three upcoming investor conferences during June. Karen Zaderej, chairman, CEO, and president will present at the Jefferies 2019 Healthcare Conference in New York City. Peter J. Mariani, chief financial officer, will present at the William Blair 39th Annual Growth Stock Conference in Chicago.
AxoGen (AXGN) delivered earnings and revenue surprises of -7.14% and 4.89%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Alachua, Florida-based company said it had a loss of 24 cents. Losses, adjusted for stock option expense and non-recurring costs, were 15 cents per share. The results did not ...
ALACHUA, Fla., May 08, 2019 -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral.
Axogen, Inc. (AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced it increased the size of its Board of Directors to nine members and appointed Quentin S. Blackford and Alan M. Levine to fill the open positions effective May 15, 2019. Blackford was also appointed to the Audit Committee, and Levine was appointed to the Audit Committee and the Governance and Nominating Committee.
AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The study will support the submission of a Biologic License Application (BLA) to the FDA for Avance® Nerve Graft. The FDA-approved RECON Study design includes a Statistical Analysis Plan that outlines a blinded interim analysis of the pooled standard deviation for the primary endpoint measure from the first 80 enrolled subjects. The pooled standard deviation is a key statistical assumption used to determine the appropriate sample size for the study.
Axogen, Inc. (AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that it will report first quarter 2019 financial results on Wednesday, May 8, 2019 after the market closes. Axogen management will host an investment-community conference call and webcast following the release at 4:30 p.m. ET. Axogen (AXGN) is the leading company focused specifically on the science, development and commercialization of technologies for peripheral nerve regeneration and repair.
How far off is AxoGen, Inc. (NASDAQ:AXGN) from its intrinsic value? Using the most recent financial data, we'll take a look at whether the stock is fairly priced by taking the expected future cash flows and discounting them to toda...
NEW YORK , March 22, 2019 /PRNewswire/ -- 22 nd Century Group (XXII) Lifshitz & Miller announces investigation into possible securities laws violations in connection with allegations that XXII's stock ...
Shareholder rights law firm Robbins Arroyo LLP reminds shareholders that purchasers of AxoGen, Inc. (AXGN) filed a class action complaint against the company for alleged violations of the Securities Exchange Act of 1933 and Securities Act of 1934 pursuant to the company's November 2017 Secondary Public Offering ("SPO") and/or May 2018 SPO and/or between August 7, 2017 and December 18, 2018. AxoGen develops and markets surgical solutions for peripheral nerves.
NEW YORK, March 11, 2019 -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies..
NEW YORK, NY / ACCESSWIRE / March 11, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against AxoGen, Inc. ("AxoGen" or the "Company") ...
ClaimsFiler, a FREE shareholder information service, reminds investors that they have only until March 11, 2019 to file lead plaintiff applications in a securities class action lawsuit against AxoGen, Inc. (AXGN). Investor losses must relate to purchases of the Company’s securities in connection with its November 2017 or May 2018 secondary public offering or between August 7, 2017 and December 18, 2018. This action is pending in the United States District Court for the Middle District of Florida.
NEW YORK, March 10, 2019 -- Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of AxoGen, Inc., Markel.
NEW YORK, NY / ACCESSWIRE / March 10, 2019 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have ...
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with large financial interests that they have only until March 11, 2019 to file lead plaintiff applications in a securities class action lawsuit against AxoGen, Inc. (AXGN). Investor losses must relate to purchases of the Company’s securities in connection with its November 2017 or May 2018 secondary public offering or between August 7, 2017 and December 18, 2018.
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against AxoGen, Inc. (“AxoGen” or “the Company”) (NASDAQ: AXGN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company’s shares pursuant to and/or traceable to AxoGen’s Registration Statement and Prospectus issued in connection to the Company’s November 2017 secondary public offering (“November SPO”), and/or the Company’s Registration Statement and Prospectus issued in connection with the Company’s May 2018 secondary public offering (“May SPO”), and/or between August 7, 2017, and December 18, 2018, inclusive (“the Class Period”), are encouraged to contact the firm before March 11, 2019.
FINAL DEADLINE REMINDER: AxoGen investors may, no later than March 11, 2019, seek to be appointed as a lead plaintiff representative of the class. According to the complaint, AxoGen provides surgical solutions for physical damage or discontinuity to peripheral nerves.